Supplemental material
Leukemia & Lymphoma
Volume 57, 2016 - Issue 4
Open access
6,978
Views
60
CrossRef citations to date
0
Altmetric
Reviews
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update
Bruce D. ChesonLombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA; Correspondence[email protected]
, Wolfram BruggerSchwarzwald-Baar Clinic, University of Freiburg, Villingen-Schwenningen, Germany;
, Gandhi DamajUniversity Hospital, University of Basse-Normandie, Caen, France;
, Martin DreylingMedical Clinic, University Hospital of Munich, Munich, Germany;
, Brad KahlUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA;
, Eva KimbyCenter for Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden;
, Michinori OguraDepartment of Hematology, Tokai Central Hospital, Gifu, Japan;
, Eckhart WeidmannDepartment of Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany;
, Clemens-Martin WendtnerKlinikum Schwabing, Academic Teaching Hospital of University of Munich, Munich, Germany;
& Pier Luigi ZinzaniInstitute of Hematology, University of Bologna, Bologna, Italy
show all
Pages 766-782
|
Received 26 Jun 2015, Accepted 19 Sep 2015, Published online: 23 Nov 2015
Related Research Data
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma
Source:
Elsevier BV
A safety profile of medications used to treat Waldenström’s macroglobulinemia
Source:
Informa UK Limited
Pharmacokinetics and Excretion of 14C-Bendamustine in Patients with Relapsed or Refractory Malignancy
Source:
Springer Science and Business Media LLC
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
Source:
Springer Science and Business Media LLC
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Source:
American Society of Hematology
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone
Source:
Springer Science and Business Media LLC
Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma
Source:
Springer Science and Business Media LLC
A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
Source:
Wiley
Therapies for Peripheral T-Cell Lymphomas
Source:
American Society of Hematology
Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
Source:
American Society of Clinical Oncology (ASCO)
Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
Source:
Springer Science and Business Media LLC
Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies
Source:
Elsevier BV
A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma
Source:
American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.
Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Source:
Springer Science and Business Media LLC
Correspondence
Source:
Wiley
Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in
Source:
Springer Science and Business Media LLC
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
Source:
American Society of Clinical Oncology (ASCO)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Source:
American Society of Clinical Oncology (ASCO)
Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
Source:
Informa UK Limited
Bendamustine and infections
Source:
Wiley
Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Source:
American Society of Clinical Oncology (ASCO)
Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
Source:
American Association for Cancer Research (AACR)
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Source:
Elsevier BV
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
Source:
Springer Science and Business Media LLC
Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma
Source:
Wiley
Optimizing Chemotherapeutic Strategies for Peripheral T-Cell Lymphomas
Source:
Elsevier BV
United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma
Source:
Wiley
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.